Monopar Therapeutics Inc.

NasdaqCM:MNPR Stock Report

Market Cap: US$116.4m

Monopar Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chandler Robinson

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage32.6%
CEO tenure10yrs
CEO ownership1.1%
Management average tenure5.8yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Aug 13
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Feb 27
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?

Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

Mar 02
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?

We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Nov 16
We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully

Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive

Oct 05

We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Jul 30
We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate

Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

Mar 28
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Jul 15
We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Mar 26
Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation

Monopar nabs U.S. patent covering camsirubicin

Dec 22

Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19

Dec 10

Monopar launches validive mid-stage study in chemo-induced oral mucositis

Dec 08

Monopar Therapeutics EPS beats by $0.02

Nov 12

CEO Compensation Analysis

How has Chandler Robinson's remuneration changed compared to Monopar Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$7m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$2mUS$580k

-US$8m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$2mUS$550k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$10m

Mar 31 2022n/an/a

-US$10m

Dec 31 2021US$1mUS$525k

-US$9m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$7m

Dec 31 2020US$2mUS$504k

-US$6m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$4m

Mar 31 2020n/an/a

-US$4m

Dec 31 2019US$541kUS$386k

-US$4m

Sep 30 2019n/an/a

-US$4m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$1mUS$375k

-US$3m

Sep 30 2018n/an/a

-US$3m

Jun 30 2018n/an/a

-US$17m

Mar 31 2018n/an/a

-US$17m

Dec 31 2017US$401kUS$331k

-US$17m

Compensation vs Market: Chandler's total compensation ($USD1.78M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Chandler's compensation has increased whilst the company is unprofitable.

CEO

Chandler Robinson (40 yo)

10yrs

Tenure

US$1,778,655

Compensation

Dr. Chandler D. Robinson, M.D., MBA, MSc, Co-Founded Monopar Therapeutics Inc. in 2010 and has been Chief Executive Officer and Director since December 2014 and serves as President. Among his previous expe...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Starr
Co-Founder & Independent Executive Chairman of the Board10yrsUS$264.04k0.29%
$ 331.9k
Chandler Robinson
Co-Founder10yrsUS$1.78m1.06%
$ 1.2m
Andrew Cittadine
Chief Operating Officer3.5yrsUS$911.14k0.76%
$ 879.1k
Karthik Radhakrishnan
CFO, Principal Accounting Officer & Principal Financial Officerless than a yearno data0.029%
$ 34.2k
Patrice Rioux
Acting Chief Medical Officer8yrsno datano data

5.8yrs

Average Tenure

53yo

Average Age

Experienced Management: MNPR's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Starr
Co-Founder & Independent Executive Chairman of the Board10yrsUS$264.04k0.29%
$ 331.9k
Chandler Robinson
Co-Founder10yrsUS$1.78m1.06%
$ 1.2m
Michael Brown
Independent Director10yrsUS$126.04k0.59%
$ 687.4k
Raymond Anderson
Independent Director7.7yrsUS$136.54k0.10%
$ 118.5k
Arthur Klausner
Independent Director7.3yrsUS$128.54k0.12%
$ 136.1k
Kim Tsuchimoto
Director1.8yrsUS$848.44k0.22%
$ 253.3k

8.8yrs

Average Tenure

65.5yo

Average Age

Experienced Board: MNPR's board of directors are considered experienced (8.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:38
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Monopar Therapeutics Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Kumaraguru RajaBrookline Capital Markets
Sean LeeH.C. Wainwright & Co.